|
KMID : 1094720140190050780
|
|
Biotechnology and Bioprocess Engineering
2014 Volume.19 No. 5 p.780 ~ p.789
|
|
|
Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding
|
|
Jung Sang-Taek
Kang Tae-Hyun
Kim Dong-Il
|
|
|
Abstract
|
|
|
|
The clinical use of therapeutic antibodies has increased sharply because of their many advantages over conventional small molecule drugs, particularly with respect to their affinity, specificity, and serum stability. Tumor or infected cells are removed by the binding of antibody Fc regions to Fc gamma receptors (FcγRs), which stimulate the activation of immune effector cells. Aglycosylated full-length IgG antibodies expressed in bacteria have different Fc conformations compared to their glycosylated counterparts produced in mammalian cells. As a result, they are unable to bind FcγRs, resulting in little to no activation of immune effector cells. In this study, we created a combinatorial library randomized at the upper CH2 loops of an aglycosylated Fc variant (Fc5: E382V/M428) and used a high-throughput flow cytometry library screening method, combined with bacterial display of homodimeric Fc domains for enhanced FcγR binding affinity. The trastuzumab Fc variant containing the identified mutations (Q295R, L328W, A330V, P331A, I332Y, E382V, M428I) not only exhibited over 120 fold higher affinity of specific binding to FcγRI than wild type aglycosylated Fc, but also retained pH-dependent FcRn binding. These results show that an aglycosylated antibody expressed in bacteria can be evolved for novel FcγR affinity and specificity.
|
|
|
KEYWORD
|
|
|
antibody Fc, directed evolution, FcγRI (CD64), neonatal Fc receptor (FcRn), effector functions
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|